Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Perinatal outcomes of pregnant women having SARS-CoV-2 infection

Sevcan Arzu Arinkan a, *, Ezgi Ceren Dallı Alper b, Gunes Topcu b, Murat Muhcu b

a Department of Obstetrics and Gynecology, Haydarpasa Numune Training and Research Hospital, University of Health Sciences, Istanbul, Turkey
b Department of Obstetrics and Gynecology, Unnaniye Training and Research Hospital, University of Health Sciences, Istanbul, Turkey

Abstract

Objectives: Aim of this study is to evaluate the prognosis of pregnant women having SARS-CoV-2 infection and investigate whether there was a difference in perinatal outcomes between pregnant women who had SARS-CoV-2 infection and those who did not.

Materials and methods: This prospective observational study was conducted with 116 singleton pregnancies. Cases enrolling in the study were divided into two groups. While those in the first group had a history of SARS-CoV-2 infection (n = 46) the second group consisted of healthy pregnant women (n = 70).

Results: Emergency Cesarean section was performed on three SARS-CoV-2 infected pregnancies (30, 33 and 34 gestational weeks). Intensive care unit admission was required for all three cases after delivery and two of them died. Among the pregnancies that had an infection in the third trimester, 71.4% (n = 20) of them had delivery in 14 days after diagnosis and 17.4% (n = 8) of their newborns were followed up at newborn intensive care unit. Overall, only one newborn had a positive swab test result for SARS-CoV-2. There was no statistically significant difference between groups regarding their delivery week (37.02 ± 5.85 vs 38.5 ± 2.33). Similarly, there was no significant difference between groups, concerning mean age, parity, and birth weight (P = 0.707, P = 0.092, P = 0.334; P < 0.05). Furthermore, the difference between SARS-CoV-2 infected pregnancies that were followed up as inpatient or outpatient with respect to the delivery week and birth weight was not significant (p > 0.05). Also, APGAR 5 scores of hospitalized women (9.3 ± 1.1) were found to be lower than the outpatient group (9.8 ± 0.8) (P = 0.043; p < 0.05).

Conclusion: No significant difference was detected between groups in terms of the delivery week, birth weight, and APGAR scores. The inpatient group was found to have lower APGAR 5 scores.

© 2021 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) was first reported in Wuhan, China in December 2019, and has infected millions of people around the world causing thousands of deaths. This major public health problem affected pregnancies, as well. The pregnancy rate of 15–44 aged women with laboratory-confirmed SARS-CoV-2 infection was reported as 9% [1]. It is suggested that SARS-CoV-2 infects the host cell by using a similar receptor such as angiotensin-converting enzyme 2 (ACE2). Expression in endometrium tissue and placenta was reported, too [2]. Regarding the outcome of such an expression, it can be argued that the expression of viral receptors increases vulnerability to infection theoretically. Yet, so far, pregnancy has been known not to be a condition that adversely affects the SARS-CoV-2 infection course [3,4]. In the literature, some studies have pointed the association between SARS-CoV-2 infection and preterm birth and increased maternal intensive care unit (ICU) need. However, adverse fetal and maternal outcomes in patients infected during pregnancy are still the subject of research.

In this study, we, primarily, aimed to evaluate the prognosis of pregnant women who were treated for SARS-CoV-2 infection. Secondly, study also focused on determining whether there was a difference in perinatal outcomes between pregnant women who had SARS-CoV-2 infection during their pregnancies and those who did not.

* Corresponding author. Sağlık Bilimleri Üniversitesi, Hamidiye Hemşirelik Fakültesi, Uskudar, Istanbul, Turkey.
E-mail address: arzuarinkan@gmail.com (S.A. Arinkan).

https://doi.org/10.1016/j.tjog.2021.09.001
1028-4559/© 2021 Taiwan Association of Obstetrics & Gynecology. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Material and methods

This prospective observational study was conducted at the Department of Obstetrics and Gynecology, Umnanjiye Research and Training Hospital, Turkey which was a tertiary care referral center for COVID-19 between June 2020 and January 2021. A total of 116 pregnancies that were delivered in our hospital were included in the study. Cases included in the study were divided into two groups. Those in the first group had a history of SARS-CoV-2 infection and the second group consisted of healthy pregnant women.

Pregnancies who were followed up at the pandemic clinic and giving birth at our hospital were included in the study group. Healthy pregnant women giving birth at our hospital were included in the control group. A reverse transcription-polymerase chain reaction (RT-PCR) test of a nasopharyngeal swab was used to confirm the diagnosis [5].

Demographic and obstetric characteristics of all the pregnancies were also reviewed. Additionally, study also reviewed parameters such as the gestational week that the mother was infected, symptoms, drugs administered for the treatment of SARS-CoV-2 infection, gestational week of birth, route of delivery, APGAR scores, and need for neonatal intensive care unit (NICU). During the study, neonatal testing for SARS-CoV-2 was performed on infants born within 3 weeks of maternal infection or when it was clinically indicated within 24 h subsequent to the delivery. Regarding the infants born to symptomatic mothers, routine isolation from mothers was applied [3].

The study was approved by the Local Ethics and Clinical Investigation Committee on 21.05.2020 (Approval Record Number is 215). Informed consent was taken from all patients. The Statistical Package for the Social Sciences (SPSS v21, Chicago, IL, USA) was used for statistical analyses. Descriptive statistics are presented as mean ± standard deviation for normally distributed data. The relationship between the categorical variables was examined using the chi-square test. The Kolmogorov–Smirnov test was used for the assessment of the normality of the data. The Mann–Whitney test was used for the data that were not normally distributed. The results were evaluated against a confidence interval of 95%, and P-value < 0.05 for statistical significance.

Results

This study was conducted with 116 pregnancies between June 2020 and January 2021. General characteristics of groups are shown in Table 1. There was no significant difference with respect to the delivery week between pregnant women who had SARS-CoV-2 infection and those who did not (37.02 ± 5.85 vs 38.5 ± 2.33) (P = 0.206; P > 0.05). Also, there was no significant difference between groups after controlling mean age, parity, and birth weight (P = 0.707, P = 0.092, P = 0.334; P > 0.05).

Among 51 SARS-CoV-2 infected pregnancies, 46 women were included in the study (3 of them have not delivered yet and two of them gave birth at a different hospital). Amongst the infected cases, 10.9% (n = 5) had infection in the first trimester, 28.3% (n = 13) in the second trimester and 60.8% (n = 28) in the third trimester. SARS-CoV-2 infected cases were admitted to emergency service with complaints of cough (41.3%), dyspnea (26.1%), myalgia (15.2%), loss of taste (2.2%), fever (8.7%), fatigue, and diarrhea (2.2%). The mean duration from admission to symptom onset was 2.85 ± 2.28 days. In this study, we should also note that, 67.4% (n = 31) of the infected cases were hospitalized. Leucocyte and lymphocyte count at admission ranged from 1221 to 21,330 cells/mm³ and from 590 to 5050 cells/mm³ respectively. Relevant blood test results at admission are shown in Table 2. As for the treatment process, all hospitalized SARS-CoV-2 infected pregnant women received low molecular weight heparin therapy. Overall, 32.6% (n = 15) received hydroxychloroquine, 13.3% (n = 6) were given favipiravir, 17% (n = 8) were administered Kalera (50 mg ritonavir plus 200 mg lopinavir) and 39.1% (n = 18) did not receive any treatment. One patient was given both hydroxychloroquine and favipiravir treatment. O₂ supplementation was required for five patients (10.9%). There was no significant difference between SARS-CoV-2 infected pregnancies that were followed up as inpatient or outpatient regarding their delivery week (36.9 vs 37.1 gestational weeks) (P = 0.211; P > 0.05). Moreover, there was no significant difference in terms of birth weight and APGAR 1 scores (P = 0.265, P = 0.214; P > 0.05). However, APGAR 5 scores of hospitalized women (9.3 ± 1.1) were found to be lower than the outpatient group (9.8 ± 0.8) (P = 0.043; P < 0.05) (Table 3).

All deliveries of symptomatic cases were performed without delayed cord clamping and skin-to-skin contact. All newborns were isolated immediately after the delivery. Emergency CS was performed on three pregnancies (at 30, 33 and 34 gestational weeks) when they were being followed up in the SARS-CoV-2 inpatient clinic. All these women needed ICU admission after their delivery and two of them died due to of SARS-CoV-2 complications (Table 4). Among the pregnancies who had an infection in the third trimester, 71.4% (n = 20) had delivery in 14 days after diagnosis and 17.4% (n = 8) of newborns were followed up at NICU. Only one newborn had a positive result for SARS-CoV-2. The swab test results of newborns whose mothers died because of the complications stemming from the infection were negative (Table 4).

The preterm delivery ratio was 13.04% (n = 6) among pregnant women having SARS-CoV-2 infection. As for the cases who had an infection in the first trimester, two of them had abortions in 7 and 18 gestational weeks, and none of the newborns were reported to have a fetal anomaly.

Discussion

The SARS-CoV-2 infection has spread quickly and become a major health problem in the world. During this pandemic period,
pregnant women without comorbidities are reported to have developed similar clinical features with nonpregnant patients. In a cohort study including 252 SARS-CoV-2 positive and 3122 negative pregnant women, adverse pregnancy outcomes were found to be similar. It has been concluded that SARS-CoV-2 infection in pregnancy did not lead to adverse outcomes [4]. The neonatal infection rate was reported as 3% [4]. However, adverse fetal and neonatal outcomes are yet to be investigated. This study aimed to investigate and determine whether there is an association between SARS-CoV-2 infection and perinatal outcomes.

The risk of vertical transmission during pregnancy is yet to be identified since there is limited data available about the vertical transmission. However, it is suggested that in utero transmission can occur at a rate of 3% [6]. Ozturk et al., analyzed the abortus material of 21 pregnant women with laboratory-confirmed SARS-CoV-2 infection. Placenta and curettage samples were found to be negative for SARS-CoV-2 RNA [7]. Gao et al. investigated the association of clinical characteristics and placental pathological changes in SARS-CoV-2 infected pregnancies. They studied eight placentas of pregnant women in the third trimester. SARS-CoV-2 RNA and chronic histiocytic intervillositis were not detected in placenta late 3rd trimester were reported in a retrospective study from Wuhan, China. Swab tests of all newborns were detected to be negative. Although vertical transmission was not detected, the ratio of neonatal pneumonia was found to be higher [12]. While leucocyte count was increased in 7 women, there was a decrease in lymphocyte count in 8 women. Of the patients, 94% had CS and 17% had a premature birth. Also, authors reported neither maternal nor neonatal deaths [12]. Additionally, in another review, it is reported that pregnant women did not have an increased risk of SARS-CoV-2 infection but had a higher risk of ICU need. Also, preterm birth rates were found to be higher in pregnancies with COVID-19 infection [6,13]. The rate of ICU admission and mortality rates were reported as 4% and 0.2% among pregnant women, respectively [13]. Preexisting comorbidities (high BMI, diabetes, hypertension) increase ICU and invasive ventilation needs [11,13]. Newborn to SARS-CoV-2 infected mothers had a higher risk of neonatal unit admission rates [13] as well. In another large study, the outcomes of 598 hospitalized pregnant women with SARS-CoV-2 infection between March and August 2020, were reported. Overall, 45.5% (n = 272) were asymptomatic at admission. The ratio of ICU needs among symptomatic patients was 16.2%. The maternal death ratio was detected as 1% (n = 2). It was also reported that pregnancies that had an infection during the first or second trimester were more frequently symptomatic. The ratio of preterm delivery was 23.1% in symptomatic women and 8% in asymptomatic women. In addition, premature rupture of membrane was 2.5% [14]. While cough, sore throat, and body aches were reported as the first symptoms leading

Table 2
Blood test results of SARS-CoV-2 patients at admission.

| Test                      | Minimum-Maximum | Mean ± SD         |
|---------------------------|------------------|-------------------|
| Temperature (°Celsius)     | 35.7–38.6        | 36.58 ± 0.52      |
| WBC (cells/mm³)           | 1221–21330       | 10.487 ± 3658     |
| Lymphocyte (cells/mm³)    | 590–5050         | 1903 ± 683        |
| Neutrophil (cells/mm³)    | 1277–23000       | 6894 ± 3940       |
| CRP (mg/dL)               | 0.10–34          | 2.1 ± 4.72        |
| LDH (IU/L)                | 140–909          | 308 ± 118         |
| Fibrinogen (mg/dL)        | 169–776          | 455 ± 137         |
| D dimer (mg FEU/mL)       | 640–10 000       | 2012 ± 1693       |
| Duration from admission to symptom onset (day) | 0–7 | 2.85 ± 2.28 |

WBC: white blood cell, CRP: C-reactive protein, LDH: Lactate dehydrogenase.

Table 3
Comparison of outcomes between outpatient and hospitalized SARS-CoV-2 infected pregnancies.

| Outcome                  | Inpatient group | Outpatient group |
|--------------------------|-----------------|------------------|
| Delivery week (week)     | 37.1 ± 4.4      | 36.9 ± 8.1       |
| Birth weight (gram)      | 3079 ± 781      | 3341 ± 576       |
| APGAR 1                  | 8.1 ± 1.6       | 8.6 ± 1.1        |
| APGAR 5                  | 9.3 ± 1.1       | 9.8 ± 0.8        |

Mann Whitney U Test, *p < 0.05.

Table 4
Characteristics of pregnant women who were followed up at intensive care unit.

| Age Gestational week at admission | Treatment | Admission to symptom onset | Neutrophil Count (cells/mm³) at admission | Lymphocyte count (cells/mm³) at admission | D-Dimer (µg FEU/mL) at admission | Fibrinogen (mg/dL) at admission | Maternal ICU | Delivery week | Delivery route | Apagar 1-5 | NICU Fetal swab |
|-----------------------------------|-----------|-----------------------------|-------------------------------------------|-------------------------------------------|---------------------------------|-------------------------------|----------------|-------------|----------------|------------|----------------|
| 1 33 30                            | Kaletra   | 6 days                      | 23,000                                    | 1600                                      | 1590                            | 613                            | 8th day-EX | 31 CS       | 2–5            | yes        | Negative       |
| 2 32 33                            | Kaletra   | 3 days                      | 11,910                                    | 1500                                      | 2100                            | 776                            | 10 days       | 34 CS       | 7–9            | yes        | None           |
| 3 35 34                            | Favipiravir| 5 days                      | 10,850                                    | 1140                                      | 5120                            | 445                            | 17th day-EX | 34 CS       | 8–9            | yes        | Negative       |
pregnant women to be tested [15] fever and myalgia were reported less among pregnant women compared to non-pregnant patients [13]. Similarly, we detected fever less often at admission. In our study, the most common symptoms at admission were found to be cough (41.3%), dyspnea (26.1%), and myalgia (15.2%). The preterm delivery ratio was 13.04% (n = 6). The median resolution time of symptoms was reported as 37 days. However, symptoms persisted 8 weeks or more amongst the 25% of pregnant women [15]. In their prospective cohort study, Hcini et al. reported that only 25% of pregnant women were symptomatic at admission. Also, they did not detect an increased risk in terms of preterm birth and CS delivery. Their study reported that pregnant women with SARS-CoV-2 infection had increased risk in terms of postpartum hemorrhage, transfusion, and intrauterine fetal demise compared to those without infection [16]. In a cohort study from Spain, outcomes of asymptomatic SARS-CoV-2 positive (n = 174) and negative pregnant women (n = 430) were compared. Authors detected higher preterm rupture of membranes among term deliveries in the asymptomatic group compared to the SARS-CoV-2 negative group. Additionally, they detected no significant difference between groups in terms of maternal and fetal outcomes [17]. Similarly, we detected no statistically significant difference between groups concerning the delivery week, birth weight, and APGAR scores.

In a multinational retrospective cohort study, 887 singleton pregnancies confirmed with RT-PCR swab test were included. Three cases of maternal death were reported. Advanced maternal age was found to be associated with adverse perinatal outcome [18]. In our study, maternal death occurred in two cases (4.3%).

Main limitation of our study is the small number of cases at inpatient and outpatient groups. We detected a mortality rate of 4.3% and there was no significant difference between pregnant women having SARS-CoV-2 infection and those who did not, when considering the delivery week, birth weight, and APGAR scores. Also, no significant difference was observed in terms of the delivery week, birth weight, and APGAR 1 scores between SARS-CoV-2 infected pregnant women who were followed up as inpatient and those who were outpatient. However, APGAR 5 scores were found to be lower in the inpatient group. Additionally, the swab test results of newborns whose mothers died due to the complications caused by infection were negative. The vertical transmission of infection is still unclear. New studies including large cases among pregnant women having severe diseases might be conducted in order to better identify vertical transmission.

Declaration of competing interest

The authors declare no conflict of interest.

References

[1] Ellington S, Strid P, Tong VT, Woodworth K, Galang RR, Zambrano LD, et al. Characteristics of women of reproductive age with laboratory-confirmed SARS-CoV-2 infection by pregnancy status - United States, January 22-June 7, 2020. MMWR Morb Mortal Wkly Rep 2020;69(25):769–75.

[2] Wong YP, Khong TY, Tan GC. The effects of COVID-19 on placenta and pregnancy: what do we know so far? Diagnostics 2021;11(1).

[3] Adhikari EH, Moreno W, Zöfke AC, MacDonald I, McIntyre DD, Collins RJR, et al. Pregnancy outcomes among women with and without severe acute respiratory syndrome coronavirus 2 infection. JAMA Netw Open 2020;3(11):e2029256.

[4] Amaral WND, Moraes CL, Rodrigues A, Noll M, Arruda JT, Mendonca CR. Maternal coronavirus infections and neonates born to mothers with SARS-CoV-2: a systematic review. Healthcare 2020;8(4).

[5] Organization WH. Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) is suspected: interim guidance. 27 May 2020.

[6] Madjunkov M, Dviri M, Librach C. A comprehensive review of the impact of COVID-19 on human reproductive biology, assisted reproduction care and pregnancy: a Canadian perspective. J Ovarian Res 2020;13(1):140.

[7] Halici-Ozturk F, Ocal FD, Aydin S, Tanacan A, Ahyan S, Altinboga O, et al. Investigating the risk of maternal-fetal transmission of SARS-CoV-2 in early pregnancy. Placenta 2021;106:25–5.

[8] Gao L, Ren J, Xu L, Ke X, Xiong L, Tian X, et al. Placental pathology of the third trimester pregnant women from COVID-19. Diagn Pathol 2021;16(1):8.

[9] Alzamora MC, Paredes T, Caceres D, Webb CM, Valdez LM, La Rosa M. Severe COVID-19 during pregnancy and possible vertical transmission. Am J Perinatol 2020;37(8):861–5.

[10] Yang Z, Liu Y. Vertical transmission of severe acute respiratory syndrome coronavirus 2: a systematic review. Am J Perinatol 2020;37(10):1055–60.

[11] Cosma S, Carosso AR, Cusato J, Borella F, Carosso M, Bovetti M, et al. Coronavirus disease 2019 and first-trimester spontaneous abortion: a case-control study of 225 pregnant patients. Am J Obstet Gynecol 2021;224(4):391–e1.

[12] Zhang L, Dong L, Ming L, Wei M, Li J, Hu R, et al. Severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) infection during late pregnancy: a report of 18 patients from Wuhan, China. BMC Pregnancy Childbirth 2020;20(1):394.

[13] Aleotry J, Stallings E, Bonet M, Yap M, Chatterjee S, Kew T, et al. Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: living systematic review and meta-analysis. BMJ 2020;370:m3320.

[14] Delahoy MJ, Whitaker M, O’Halloran A, Chai SJ, Kirley PD, Alden N, et al. Characteristics and maternal and birth outcomes of hospitalized pregnant women with laboratory-confirmed COVID-19 – COVID-NET, 13 states, March 1-August 22, 2020. MMWR Mortal Mortal Wkly Rep 2020;69(38):1347–54.

[15] Alshar Y, Gaw SL, Fisherman VJ, Chambers BD, Krakow D, Berghella V, et al. Clinical presentation of coronavirus disease 2019 (COVID-19) in pregnant and recently pregnant people. Obstet Gynecol 2020;136(6):1117–25.

[16] Hcini N, Maamri F, Picone O, Carod JF, Lambert V, Mathieu M, et al. Maternal, fetal and neonatal outcomes of large series of SARS-CoV-2 positive pregnancies in peripartum period: a single-center prospective comparative study. Eur J Obs Gynecol Perinatol 2021;257:11–8.

[17] Cruz-Lemini M, Ferriols Perez E, de la Cruz Conty ML, Cano Aguilar A, Encinas Pardilla MB, Prats Rodriguez P, et al. Obstetric outcomes of SARS-CoV-2 infection in asymptomatic pregnant women. Viruses 2021;13(1).

[18] D’Antonio F, Sen C, Mascio DD, Galindo A, Villalain C, Herrera I, et al. Maternal and perinatal outcomes in high vs low risk-pregnancies affected by SARS-CoV-2 infection (Phase-2): the WAPM (World Association of Perinatal Medicine) working group on COVID-19. Am J Obstet Gynecol MFM 2021;100329.